Novartis recalls flu vaccine
Products Novartis is recalling two batches of its flu vaccine after “visible protein aggregates” were discovered during testing.
Novartis is recalling two batches of its flu vaccine after "visible protein aggregates" were discovered during testing.
Novartis said no adverse reactions had been reported from the two batches of Agrippal suspension, issued in October (full details below). Patients who had received the vaccine should have "no cause for concern" and "no need for revaccination", it said.
"The aggregation consists mostly of viral proteins expected in the vaccine and, when observed, aggregation is transient and disappears upon shaking, as recommended in product labelling," Novartis said. "No visible protein aggregates were detected at the time of product release in any of these UK batches."
Novartis advised pharmacists holding any remaining stock of the batches to quarantine them and return them to the supplier for credit.
Enquiries regarding stock returns should be directed to Novartis Vaccines Customer Services on 08457 451500, while the company's Vaccines Medical Information line on 01748 828816 will take any medical enquiries.
Batch Number |
Expiry Date |
Pack Size |
First Distributed |
126201A |
31 May 2013 |
10 x pre-filled syringes |
9 Oct 2012 |
126102 |
31 May 2013 |
10 x pre-filled syringes |
17 Oct 2012 |